Pioneering the Next Generation of Single-Tube Ultra-Multiplex PCR: Discover Multiplex Probe Amplification (MPA) Technology
Multiplex Probe Amplification (MPA) is a globally patented, groundbreaking nucleic acid detection technology based on advanced melting curve analysis. Engineered to meet the demanding needs of modern clinical laboratories, our Multiplex Probe Amplification (MPA) technology combines the precision of molecular diagnostics with unparalleled efficiency.
By leveraging a unique double-stranded probe structure (THO-PCO complex) and a target-dependent probe consumption mechanism, MPA enables the detection of 4 to 6 distinct targets within a single fluorescence channel. Combined with real-time PCR, it shatters traditional multiplexing barriers—amplifying and detecting over 16 targets in a single tube. Deliver rapid, broad-spectrum, and precise diagnostic insights with unprecedented efficiency.
Why Choose MPA Technology?
In a landscape often dominated by closed-system platforms with limited target capacity, MPA offers a highly competitive, scalable, and cost-effective alternative for syndromic testing:
· Unmatched Multiplexing & High Throughput: Go beyond the limitations of conventional 4-target RT-PCR. MPA achieves 16+ targets per tube, scaling up to 31 targets in dual-tube assays. It is ideal for high-throughput batch screening, syndromic testing, and large-scale epidemiological surveillance.
· Open-Platform Compatibility & Cost-Efficiency: Unlike closed IVD systems that lock laboratories into expensive proprietary instruments, MPA is platform-agnostic. It integrates seamlessly with standard 4-channel real-time PCR platforms (e.g., Hongshi), significantly lowering operational costs and eliminating the need for dedicated capital equipment.
· Uncompromising Sensitivity & Specificity: Achieve a limit of detection (LOD) as low as 100 copies/reaction (400 copies/mL), ensuring reliable early detection of trace pathogens. Our patented fluorescent probe design guarantees exceptional specificity and effectively prevents false-positive results.
· Robust Performance & Maximum Biosafety: Engineered for real-world clinical and field environments, MPA tolerates complex sample matrices, including 10% blood and 100μg/mL of common drugs. Furthermore, the fully closed-tube melting curve reaction design completely eradicates the risk of amplicon aerosol contamination.
· Rapid Sample-to-Answer Workflow: Drive faster clinical decisions with highly streamlined protocols. Comprehensive respiratory panels can deliver actionable results in just 150 minutes from sample extraction to final report.
Comprehensive Syndromic Solutions Across Clinical Settings
MPA empowers a diverse portfolio of comprehensive diagnostic panels, supporting healthcare professionals with actionable results across various infectious disease states:
· Respiratory Infections Panels: Confront complex respiratory outbreaks with confidence. Our portfolio includes a 12-plex viral panel (covering Influenza A, Influenza B, RSV, Adenovirus, SARS-CoV-2,etc.) and a 15-plex bacterial and atypical pathogen panel. Together, they provide a flexible "1+1" diagnostic strategy for complete respiratory health management.
· Precision HPV Genotyping & Cervical Cancer Screening: Tailored diagnostic assays for diverse clinical pathways: a 14-genotype HPV E6/E7 mRNA test for precision risk stratification of high-grade lesions, a broad 31-genotype HPV DNA test for standardized mass population screening, and targeted clinical research.
· Expanding Infectious Disease Portfolios: Rapidly identify complex co-infections with our highly scalable technology. We offer a 14-plex fungal infection panel, a 9-plex gastrointestinal viral panel, and a 13-plex gastrointestinal bacterial panel—each requiring just a single reaction tube.
Core Advantages
· Patented Innovation: Globally recognized, proprietary multiplexing technology.
· Ultra-Multiplexing: Detect multiple targets simultaneously in a single real-time PCR tube.
· Streamlined Workflow: Easy to operate, significantly reducing hands-on time and human error.
· Rapid Turnaround: Deliver actionable clinical results in just 120-150minutes.
· High Throughput: Maximize efficiency with up to 94 samples per single run.
· Platform Agnostic: Fully compatible with standard open-system fluorescent PCR instruments.
· Automated Interpretation: Smart software ensures objective, rapid, and clear reporting.
· Built-in Quality Control: Integrated internal standards guarantee reliable and accurate performance for every run.
Proven Performance. Global Recognition.
Biotron MPA-powered diagnostic solutions (including the Respiratory 12-plex and HPV 31-plex kits) are fully certified and widely adopted across national clinical institutions. The clinical utility and analytical excellence of MPA have been rigorously validated through extensive multi-center clinical trials. Furthermore, our technology's robustness is consistently recognized globally, with findings published in peer-reviewed journals.
Dedicated Partnership & Support Backed by a specialized R&D team with deep expertise in molecular diagnostics, Biotron delivers more than just reagents. We provide comprehensive technical training, highly responsive after-sales support, and collaborative research opportunities. We are dedicated to partnering with global research institutions and enterprises to drive the future of in vitro diagnostics.
Products Based on MPA Technology
